Kaitlyn Bader, Editor

Experts in the field share why they enjoyed the 5th Annual Revolutionizing Atopic Dermatitis Conference and why it is unique.

Catch up on all coverage from Revolutionizing Atopic Dermatitis.

New data from RAD 2023 revealed the results of assessing the independent and combined effects of itch and skin severity on patient-reported symptoms and QoL.

Candrice Heath, MD, FAAP, FAAD, reviewed the important conversations dermatologists need to have to understand how racism affects SOC patients with atopic dermatitis at RAD 2023.

Jonathan Silverberg, MD, PhD, MPH, presented late-breaking dupilumab data at RAD 2023.

Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.

Raj Chovatiya, MD, PhD, discusses highlights from his sessions at RAD 2023 on best practices for AD management.

Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.

De Benedetto shares her expertise on new discoveries in the science of atopic dermatitis at RAD 2023.

Bunick provides an overview of the most important highlights from his late-breaking session at RAD 2023.

A recently presented poster session from RAD 2023 evaluated a gene expression based molecular test’s differential diagnosis of psoriasis and eczema.

Catch up on coverage from the first day of Revolutionizing Atopic Dermatitis.

The RAD conference provides the chance to take a deep dive into one specific disease state in a focused setting.

The 5th annual RAD conference kicks off April 29, 2023, in Washington, DC.

ICYMI, this week we had stories about melanoma management with pembrolizumab, advances in rosacea therapy, new phase 2 data of VP-315 for BCC, and more.

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are popular for the month of April.

Learn more about the in-depth topics covered in the April 2023 issue of Dermatology Times®.

ASLAN Pharmaceuticals will present 2 late-breaking abstracts and 2 additional abstracts.

This week's edition of the Mainstream Patient features stories about addictive behaviors stemming from skin care culture, the 21 best hyaluronic acid serums, and the struggles behind finding the right vitiligo treatment.

ICYMI, this week we had stories about melanoma management with pembrolizumab, advances in rosacea therapy, new phase 2 data of VP-315 for BCC, and more.

Ruxolitinib is the first and only approved treatment for repigmentation in the European Union.

Approval has been pushed back to June 28, 2023.

Ritlecitinib was found to be effective and well-tolerated in patients aged 12 years and older.

Block spoke to the founder of the Eczema Sample Store over Instagram Live to bring more awareness to the company’s mission.

Findings published in JDD suggest topical tranexamic acid can be used as first-line monotherapy.

The expected PDUFA date is December 16, 2023.

Brella received FDA clearance last week for improving excessive underarm sweating.

This week's edition of the Mainstream Patient features stories about the risks of phenol peels, the pros and cons of skin cycling, how to prevent stretch marks during pregnancy, and more.

Data from the KEYNOTE-942 trial was presented at the American Association for Cancer Research Annual Meeting 2023.

ICYMI, this week we had stories about melanoma management with pembrolizumab, advances in rosacea therapy, new phase 2 data of VP-315 for BCC, and more.